ArriVent BioPharma appoints John Hohneker, M.D., to Board of Directors

ArriVent BioPharma, Inc.

John Hohneker, M.D., appointed to Board of Directors effective May 16, 2024 as Class II Director.
Dr. Hohneker most recently served as President & CEO of Anokion SA, and previously led R&D at Forma Therapeutics.
He held senior roles at Novartis for 14 years, including SVP and Global Head of Development, Immunology and Dermatology.
Current board seats: Carisma Therapeutics (CARM), Curis (CRIS), Sonata Therapeutics, and Trishula Therapeutics.
Received initial non-qualified stock option with fair value $352,500 vesting over three years; annual cash retainer $45,000.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Hohneker, M.D.

Class II Director

AVBP · ArriVent BioPharma, Inc.

Effective: 2024-05-16
Filed: May 16, 2024, 7:59 PM ET

On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Hohneker, M.D. was appointed as Class II Director at ArriVent BioPharma, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).

View on SEC.gov

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062528

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.